They decrease appetite and increase satiety, she said during a recent presentation of her research at Ohio States Kirwan Institute
Additionally, data from the phase 3 TROPION-Lung01 trial published in the Journal of Clinical Oncology revealed that dato-DXd showed a progression-free survival (PFS) advantage vs docetaxel, at a median of 4.4 months (95% CI, 4.2-5.6) vs 3.7 months (95% CI, 2.9-4.2), respectively (HR, 0.75
Clean math, no waste, and well within the 28-day stability window
There are patients who have had kidney failure, blood pressure issues and what we worry about as dermatologists is that, because it enhances your pigment-producing cells to produce tan or pigment, it stimulates melanocytes, which are pigment producing cells, and there have been cases of melanoma which is a very dangerous skin cancer which can be fatal